lisocabtagene maraleucel
bms
['lymphoma', 'liso-cel']
checkpoint inhibitors are ineffective in the post-car-t lbcl relapse setting in most pts the best results are seen in primary mediastinal bcl #lymphoma #cart #ash22 
Medical degree at @USAL | Internal Medicine student at @HematoCAUSA | Hematology and Hemotherapy at Hospital Ramón y Cajal @HematoRYC | PhD student at @UAHes